Sinolink Securities Co., Ltd. (600109.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Sep 9Sep 14Sep 17Sep 22Sep 28Oct 8Oct 13Oct 16

Key dataOct 16, 2026

OpenCNY 8.19

From 52W high−18.92%

Volume24.67M

Market capCNY 31.61B

P/E (TTM)13.9x

P/S (TTM)3.3x

Div yield0.99%

Key dataOct 16, 2026

Open

CNY 8.19

From 52W high

−18.92%

Volume

24.67M

Market cap

CNY 31.61B

ValuationView details →

P/E (Fwd)

10.0x

EV/EBITDA

−9.4x

P/E (TTM)

13.9x

RSI (14)

39.7

MomentumView details →

1D Return

+0.71%

YTD Return

−13.12%

ValuationView details →

P/E (Fwd)

10.0x

P/E (TTM)

13.9x

EV/EBITDA

−9.4x

EV/Sales

−3.1x

P/S (TTM)

3.3x

P/B (TTM)

0.9x

ProfitabilityView details →

Gross Margin

—

Net Margin

26.52%

EBITDA Margin

33.39%

ROE (TTM)

6.61%

ROA (TTM)

1.40%

Asset Turnover

0.06x

GrowthView details →

Revenue YoY

+27.36%

EPS YoY

+26.76%

FCF YoY

+602.82%

Revenue CAGR 3Y

+13.83%

EPS CAGR 3Y

+21.68%

EBITDA YoY

—

MomentumView details →

1D Return

+0.71%

YTD Return

−13.12%

1Y Return

−19.60%

RSI (14)

39.7

vs 50D SMA

−4.70%

vs 200D SMA

−7.81%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

—

Quick Ratio

—

Div Yield

0.99%

Div Rate

CNY 0.08

Div Growth 1Y

−33.33%

EarningsView details →

EPS (Actual)

CNY 0.19

EPS Surprise

0.00%

Beats (12Q)

0/12

Next Q EPS Est

CNY 0.20

Avg Surprise (4Q)

0.00%

Rev Surprise

−2.16%

Financials snapshotView financials →

Revenue (TTM)

9.00B

Net Income (TTM)

2.39B

Op. CF (TTM)

23.95B

Next earningsOct 31, 2026 →

Latest newsMore news →

Hongta Securities, Zhongtai Securities, Guolian Minsheng Securities, Changjiang Securities and Huaan Securities each disclosed new share buyback plans, with cancellation-style buybacks becoming more common among Chinese listed brokerages.17d ago

At the 2026 WCLC in Seoul, Chinese innovative oncology drugs were presented, including Akeso's ivonescimab showing superior head-to-head results over pembrolizumab in first-line NSCLC, and Hansoh/Yilian B7-H3 ADC entering the plenary session.23d ago

Similar companies

Brookfield Finance Inc. 4.50% PBNJ Interactive Brokers Group, Inc.IBKR 东兴证券601198.SH 华鑫股份600621.SH 华创云信600155.SH Aju IB Investment Co., Ltd.027360.KQ Find similar companies →

Latest newsMore news →

Hongta Securities, Zhongtai Securities, Guolian Minsheng Securities, Changjiang Securities and Huaan Securities each disclosed new share buyback plans, with cancellation-style buybacks becoming more common among Chinese listed brokerages.17d ago At the 2026 WCLC in Seoul, Chinese innovative oncology drugs were presented, including Akeso's ivonescimab showing superior head-to-head results over pembrolizumab in first-line NSCLC, and Hansoh/Yilian B7-H3 ADC entering the plenary session.23d ago